Natera: Strong Execution, Growing Signatera MRD Franchise, and Multiple Catalysts Support Buy Rating and $260 Target

Analyst Mark Massaro of BTIG reiterated a Buy rating on Natera, with a price target of $260.00.

Mark Massaro has given his Buy rating due to a combination of factors, primarily Natera’s strong recent execution and robust growth outlook. He highlights that the company ended the year with significantly higher-than-expected revenue and test volumes, especially in oncology, and is already generating positive free cash flow, which reinforces confidence in the sustainability of the business model.

At the same time, he points to Natera’s solid 2026 revenue guidance, operating leverage, and the powerful growth trajectory of its Signatera MRD franchise, including both rising test volumes and a clear path to higher pricing. Massaro also underscores a rich pipeline of potential catalysts—from guideline updates and reimbursement expansion to new product launches and international approvals—which together support his $260 price target and the view that the shares remain attractive at current levels.

According to TipRanks, Massaro is an analyst with an average return of -3.7% and a 34.29% success rate. Massaro covers the Healthcare sector, focusing on stocks such as GeneDx Holdings, Guardant Health, and Personalis.

In another report released today, TipRanks – Google also reiterated a Buy rating on the stock with a $224.00 price target.